Somnics GmbH of Frankfurt am Main at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Somnics GmbH

Stichlingstrasse 1, 60327 Frankfurt am Main
Germany
Telephone +49-69-24003626
info@somnics.com

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is main exhibitor of

Hall map

MEDICA 2021 hall map (Hall 11): stand B26

Fairground map

MEDICA 2021 fairground map: Hall 11

Contact

Jimmy Fan

Northern Europe & Latin America Sales Representative
Sales & Marketing Department

Woody Chou

Southern Europe & Africa Sales Representative
Sales & Marketing Department

Eric Chen

Sales VP
Sales & Marketing Department

Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Company news

Date

Topic

14 Sep 2021

Somnics Presented iNAP One Sleep Therapy System in PHARMEDI Vietnam 2021 virtual exhibition

Somnics, Inc. will honorably present its Taiwan Excellence awarded Obstructive Sleep Apnea (OSA) treatment solution - iNAP® One Sleep Therapy System to join Pharmedi Vietnam 2021 virtual exhibition from 9/15 – 10/15. Pharmedi Vietnam, considered to be the largest and most influential professional regular exhibition in the field of medical and health care in Vietnam, as well as one of the well-known professional medical exhibitions in Southeast Asia.

Citing on a 2019 worldwide study from The Lancet Respiratory Medicine, suggested that 936 million individuals in the age 30-69 group may have mild-to-severe OSA (AHI≥5), including 425 million with moderate-to-severe OSA(AHI≥15). Countries with the highest numbers of OSA individuals were China, followed by the U.S., India, and Brazil; rounding out the top 10 were Pakistan, Russia, Nigeria, Germany, France and Japan, with positive correlation to country population.

But how about in Vietnam? On a sleep medicine conference held around year-end 2018 at Pham Ngoc Thach University of Medicine, Dr. Duong Quy Sy, Chairman of the ASEAN Sleep Federation, said “OSA is a serious pathology and major risk factor for cardiovascular diseases.” The serious sleep disorder impairs quality of life, as well as intellectual and professional performances, and can also lead to accidents in the workplace and in traffic, and he added “an estimated 800,000 people in Vietnam suffer from obstructive sleep apnea syndrome” but most of them are undiagnosed. Which means, Vietnam is a big and undeveloped market for OSA treatments such as CPAP, dental devices and surgeries, or innovative therapy alternatives like iNAP® One from Somnics.

Unlike current first-line OSA therapy such as CPAP, the iNAP® One therapy device using “intraoral negative air pressure” that treats OSA differently and without a mask: it delivers a light, oral vacuum to comfortably open the airway while breathing normally through the nose during sleep. The system has a soft, flexible oral interface that enables excellent wearing comfort; its quiet battery-powered console with the size of a smartphone makes it ultra-portable for any situation. Somnics developed a tele-health OSA Remote Management System, with iNAP® Lab+ APP been installed on smart mobile devices, allowing users to see their own OSA treatment records. Since data been uploaded to the cloud platform, physicians can track and analysis, accomplishing maximum effects for sleep therapy.

Since its launch in 2017, iNAP® One Sleep Therapy System has earned awards from iF Design in Germany, A’ Design in Italy, holding marketing authorizations in Taiwan(TFDA), USA(FDA), EU(CE) and Southeast Asian countries. It also achieved the 2021 Taiwan Excellence award, the symbol of innovation and manufacturing golden standard for Taiwanese products.

Recently, Somnics leverages its knowledge, experience and quality management system in developing and manufacturing iNAP®, as the V&V domain of medical device, been capable of developing innovative medical device solutions in accordance with its CDMO clients’ orders. Achievements such as a new in-vitro diagnostic device regarding PCR quality COVID-19 at-home test, will also be presented in 2021 Taiwan Excellence Pavilion at Pharmedi Vietnam virtual exhibition virtual exhibition.

For more information of iNAP® One, please visit: https://www.inapsleep.com/en

PHARMEDI Vietnam 2021 virtual exhibition – Somnics, Inc Information for Visitors
--- Exhibition Date: September 15th – October 15th, 2021
--- Opening Hour: 10:00AM - 18:00PM ( GMT+7 )
--- Exhibition Hall: XIII) TAIWAN EXCELLENT PAVILION
--- Visitor Registration URL: https://www.pharmed.vn/registration-form

More Less

23 Jun 2021

Somnics Achieves Record-high Revenue in June Buoyed by Strong Demand of PCR Test Kits

Somnics, Inc. today announced that its consolidated revenue for June 2021 reached NT$11.736 million, benefiting from record sales of the imported Lucira Check It COVID-19 Test Kit. It led to an annual increase of 2,156.9% in revenue in June, a record high over the same period last year as well as setting a new revenue high for a single month.

In early June, Taiwan Food and Drug Administration (TFDA) approved the project of importing at-home rapid test products, and Somnics was one of the earliest manufacturers to receive approval. Somnics subsequently introduced the Lucira™ Check It COVID-19 Test Kit, which is the first PCR-quality single-use molecular test kit for COVID-19 available in the Taiwanese market. In order to accelerate the capacity of epidemic prevention and screening for communities and enterprises, Somnics has not only provided a compelling solution through the introduction of Lucira™ to more than ten enterprises but also put the product on the shelves of selected pharmacy chains and retail channels since July 1.

According to Somnics, although the domestic epidemic situation is gradually improving and restrictions are being "partially lifted", in the next chapter against corona virus epidemic, the need for using rapid test with higher accuracy to ensure business activities can operate safely just increased rather than decreased. The company is confident that Lucira™ will continue to drive sales growth as it continues to ship orders from enterprise clients as well as respond to frequent inquiries from channel partners.

During the process of introducing COVID-19 molecular test products to Taiwan, Lucira Health, Inc. (Nasdaq: LHDX), the provider of Lucira™, recognized Somnics’ professional medical material service capabilities and the company became the first entity to obtain the overseas distributorship of Lucira™. Somnics, Inc. has officially signed a distribution agreement with Lucira Health as an exclusive distribution agent in Taiwan. In addition, new progress of iNAP® Sleep Therapy System in the U.S., South Korea and German markets in the third quarter is expected to further boost the revenue performance of Somnics in the second half of 2021.

More Less

02 Jun 2021

iNAP, A New Sleep Treatment for Apnea is Launched in San Francisco

Somnics Health announces the launch of iNAP Sleep, its innovative Obstructive Sleep Apnea (OSA) treatment and service coinciding with the annual SLEEP 2021 Conference on June 10-13 sponsored by the American Academy of Sleep Medicine. Access to iNAP Sleep is now available in most states through a direct-to-consumer digital approach and through its partnerships with board-certified sleep physicians.

iNAP Sleep provides its members with iNAP®- a new therapy, onboarding, ongoing support, and an e-commerce platform, www.inapsleep.online for its nightly OSA treatment alternative.

Olivier Lauzeral, General Manager of Somnics Health, states, "We believe that there is an unmet need for a large number of individuals who haven't yet been officially diagnosed with OSA. These individuals are aware that they have a sleep-breathing disorder, they may have heard of CPAP therapy or oral appliances and outright reject these most common sleep apnea treatments. We believe that when they discover the comfort, convenience, and form factor of iNAP, many will decide to pursue a diagnosis and treatment to address their sleep issues. Allowing more patients to be diagnosed and treated and live better lives is our main aspiration.”

The company's goal is to provide a “high-touch coaching program that maintains an adherence rate above 80% for its users,” said Lori Schulman, Director of Marketng and Patient Experience. iNAP is not for everyone; however, for most customers who are candidates and adhere, the treatment can be life-changing given the comfort, convenience, and simplicity. “As with any new therapy, some patients may take longer to acclimate. Through our dedicated coaching program, we will be able to bring more patients into full nightly compliance”, Schulman explained.

The company received FDA clearance in May 2020 and is the only FDA-cleared oral negative pressure technology for OSA on the market and is approved to treat all severities of OSA. With over 155 patents issued worldwide and 35 publications in peer-reviewed journals, this treatment option is backed up by solid clinical evidence and is significant to anyone interested in Sleep Apnea treatment.

"The sleep industry is ripe for disruption", continues Lauzeral. " I've personally been on the OSA patient’s journey, and coming from the tech world, I was frustrated by the way I was moved through the healthcare system. iNAP Sleep will provide sleep physicians and OSA patients with a new, patient-preferred alternative therapy that is simple, comfortable, effective, and easy to use. We are assembling a team of professionals who understand patients' mindsets through the diagnostics and treatment odyssey. Together, we are building a company that will provide superior care and outcomes."

Currently, most physicians prescribe Continuous Positive Air Pressure (CPAP/APAP) as first-line therapy for patients diagnosed with OSA of all severity levels. But approximately 50% of patients quit CPAP due to intolerance, inconvenience, or lifestyle issues. CPAP involves a nasal or full-face mask strapped to the patient's face, a 6' long tube, and a pump that blows air all night into the mask. Most CPAPs require an electrical connection to operate and doctors rely on Durable Medical Equipment (DME) providers for inventory and distribution. Unfortunately, most DMEs are not specialized in sleep care and do not focus on personalized patient coaching to improve adherence to therapy. Physicians need more tools in their medical toolbox to offer patients, as there is no one therapy appropriate to all patients.

About Somnics

Somnics, Inc. was established in 2011 in Taiwan and in 2020 in the US and is in commercialization phase in a number of countries: Germany, Israel, Singapore, Taiwan, Vietnam, Malaysia, and Australia. To find out more, including how to start with the iNAP Club, reselling opportunities, learn how it works, and read the broad clinical evidence, please visit www.inapsleep.online

More Less

31 May 2021

Somnics Receives GMP Certification from Korean MFDS

Somnics, Inc. announced that the company has passed the GMP approval of the Korean Ministry of Food and Drug Safety (MFDS, formerly known as the Korea Food & Drug Administration or KFDA) overseas inspection in May 2021 and is expected to obtain the product certification of the iNAP® Sleep Therapy System in the third quarter of this year. The company is joining forces with LMT Korea Co. Ltd. to enter the Korean market to benefit Obstructive Sleep Apnea patients in Korea.
 
According to Somnics, in 2020, the company signed a contract with LMT Korea Co., Ltd, based in Gyeonggi-do to promote the iNAP® Sleep Therapy System and services in Korea after obtaining certification. LMT Korea is one of the leading sleep respiratory diagnostic and treatment equipment providers in South Korea and the exclusive Korea distributor of Lowenstein respirators from Germany. With its comprehensive service coverage and close collaboration with more than 200 medical institutions, LMT holds the largest market share of CPAP devices in Korea. LMT Korea also operates LÖWENSTEIN Academy, the only sleep professional training center in South Korea. Based on similar company missions, that "patients deserve a better OSA treatment experience", LMT Korea and Somnics have joined together in a strategic partnership.
 
The iNAP® Sleep Therapy System developed by Somnics, Inc. has been marketed and promoted in many countries, including Taiwan, the United States, Germany, Hong Kong, Singapore, Thailand, etc. Korea is also one of the main target markets in Asia. According to the research report of Ansan Hospital of Korea University and Korea Center for Disease Control and Prevention, one out of every five Koreans may suffer from sleep apnea. There isstrong growth potential in sleep apnea treatment services for OSA patients in Korea, and the innovative, safe and effective iNAP® sleep therapy treatment solution offers a promising market potential in Korea.

More Less

19 Mar 2021

Somnics participated in the 2021 Smart Healthcare Expo to introduce its tele-medicine move

Somnics, Inc. (6633) develops the patented negative air pressure Obstructive Sleep Apnea (OSA) therapy device and solution. It will exhibit its iNAP products at the 2021 Smart Healthcare Expo. As IoT becomes a part of daily life, smart healthcare is a goal actively promoted by the government. At the exhibition, Somnics will share how it can help patients overcome OSA with smart interconnection technology.

In 2021 Smart Healthcare Expo (SHE Taipei), the popular “Smart Healthcare Interactive Pavilion” will exhibit three major themes: Smart Hospital, Smart Healthcare, and Smart Sleep, with the carefully planned visions and experts in different professional medical domains gathered by the sponsor. Somnics takes pleasure in exhibiting its latest negative pressure OSA treatment solution – iNAP One Sleep Therapy System. To improve the deficiencies of positive air treatment solution, the iNAP One therapy device using intraoral negative air pressure that treated the problem differently and without a mask. The system uses a soft, flexible mouthpiece, thin tubing, and a quiet battery-powered console the size of a smartphone to deliver a light, oral vacuum to comfortably open the airway while breathing normally through the nose during sleep.

Since iNAP launched into the market in 2017, it has kept making progress. The latest iNAP One model provides precise personal therapy, coming in multiple interfaces and sizes for consumers’ to choose from. It makes using it more comfortable. Embracing the smart healthcare trend, it is interconnected with the remote management system allowing users to see their own OSA treatment conditions - the data could be uploaded to the cloud platform for further tracking and analysis, accomplishing maximum effects for sleep therapy.

Somnics developed a smart interconnected OSA remote management system, including curative effect tracking iNAP Lab+ APP and treatment management cloud platform. iNAP Lab+ APP can be installed on smart mobile devices, such as smartphones, tablet computers, etc. It can also be connected to home monitoring equipment, such as an oximeter, health bracelet, etc. It records treatment data of patients every day to make it transparent. The cloud management platform can compile and track users’ treatment conditions and feedback analysis and suggestions, encouraging them to undergo continual treatment. Doctors and sleep physicians can adjust treatment plans appropriately in accordance with the data.

iNAP One Sleep Therapy System earned awards from iF Design in Germany, A’ Design in Italy, holding marketing authorizations in Taiwan (TFDA), USA (FDA), EU (CE), and Southeast Asian countries. The safety of the products is certified by many countries across the world.

2021 Smart Healthcare Expo Taipei - Opening Information
--- Date : March 23 - 26, 2021
--- Opening Time : 10 AM to 6 PM (Last day 5 PM)
--- Show Venue : TaiNEX2 (No.2, Jingmao 2nd Rd., Nangang District, Taipei, Taiwan)
--- Pavillion : Smart Healthcare Interactive Pavilion / Booth No. Q1024

More Less

12 Nov 2020

Somnics iNAP One sleep therapy system receive “2021 Taiwan Excellence Award”

Since its launch in 2017, iNAP® One Sleep Therapy System has earned awards from iF Design in Germany, A’ Design in Italy, holding marketing authorizations in Taiwan(TFDA), USA(FDA), EU(CE) and Southeast Asian countries. It also achieved the 2021 Taiwan Excellence award, a symbol of innovation and manufacturing golden standard for Taiwanese products.

Unlike current first-line OSA therapy such as CPAP, the iNAP® One therapy device using “intraoral negative air pressure” that treats OSA differently and without a mask: it delivers a light, oral vacuum to comfortably open the airway while breathing normally through the nose during sleep. The system has a soft, flexible oral interface that enables excellent wearing comfort; its quiet battery-powered console with the size of a smartphone makes it ultra-portable for any situation. Somnics developed a tele-health OSA Remote Management System, with iNAP® Lab+ APP been installed on smart mobile devices, allowing users to see their own OSA treatment records. Since data been uploaded to the cloud platform, physicians can track and analysis, accomplishing maximum effects for sleep therapy.

For more information of iNAP® One, please visit: https://www.inapsleep.com/en

More Less

27 May 2020

Somnics, Inc. (Taiwan Stock Exchange: 6633.TW) announced that it has received 510(k) Clearance from

Somnics, Inc. (Taiwan Stock Exchange: 6633.TW) announced that it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) for its iNAP® One Sleep Therapy System.

More Less

01 Nov 2016

Join the world's leading trade fair MEDICA with Somnics, Inc. at Düsseldorf from 14 - 17 November 2

Welcome to visit us at MEDICA 2016, booth at Hall 11 Stand C61.

Somnics, Inc. is a research-based and needs-driven medical device company engaging in the development of innovative treatment for sleep-disordered breathing. Our device, iNAP® Sleep Therapy System works without a mask or a bulky machine and instead uses a soft oral interface, pocket-sized and battery-powered console, which allow more patients with OSA (Obstructive Sleep Apnea) to breath naturally wherever they are.

More Less

26 Jan 2016

iNAP Sleep Therapy System won iF DESIGN AWARD in 2016

The iNAP® Sleep Therapy System by Somnics, Inc. received the prestigious iF DESIGN AWARD 2016 for the Discipline Product.

This award is recognized as a symbol of design excellence around the world and has been attributed for over 60 years to the extraordinary projects that stand out for design excellence. A total of almost 5,300 entries from about 2,500 participants from more than 50 countries were submitted to the iF DESIGN AWARD 2016, an increase of more than 500 entries compared to the preceding year. As the iF DESIGN AWARD 2016 winner, Somnics, Inc. will join the glamorous awarding ceremony, the iF design award night, at the BMW Welt in Munich on February 26 2016.

More Less

About us

Company portrait

Somnics Inc. is a Taiwan based medical device company focusing on developing innovative technologies for the treatment of Obstructive Sleep Apnea (OSA).

Somnics was founded in 2011 by Dr. Chen, Chung-Chu who himself suffered OSA and understood the deficiencies of positive air treatment solution like CPAP, oral appliances, and positional aids. He decided to take matters into his own hands and build a new therapy alternative - a treatment using “intraoral negative air pressure” that treated the problem differently and without a mask, the iNAP® Sleep Therapy technology, which is clinically proven to be a comfortable and discreet way to treat OSA.

Since then, Somnics has been improving the comfort and efficacy of the iNAP® therapy. Now iNAP® has been prescribed in countries in Europe, Asia, Australia, and available under a limited launch right in the US.

Somnics, Inc. gathered a global team of professionals who understand patients' mindsets through the treatment odyssey, also leverage Taiwan’s excellent healthcare infrastructure, engineering expertise and a strong ICT supply chain to spur the development of its innovative medical solutions.

◎ Somnics, Inc. Focus on Building Health Solution for People to Sleep and Breathe Better.
◎ Somnics, Inc. Gathered Global Talents in Medical Device to Provide Superior Outcomes.
◎ Somnics, Inc. Equipped with Domain Know-How in Medical Device Verification & Validation.

At Somnics, its mission is to provide innovative solutions and support build-up a healthcare ecosystem to satisfy the unmet needs of patients and physicians on patient-centered and user-friendly solutions for comfort and restful sleep. With its complete QMS for developing and manufacturing iNAP®, Somnics is equipped with core knowledge and experience in the domain of medical device, been capable of developing innovative medical device solutions in accordance with its CDMO clients’ orders.

Company data

Sales volume 1-9 Mio US $
Export content max. 25%
Number of employees 50-99
Area of business Imaging and diagnostics / medical equipment and devices

Company information as a PDF file